预约演示
更新于：2025-06-06
Benvitimod
本维莫德
更新于：2025-06-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-05-29), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H18O2 |
InChIKeyZISJNXNHJRQYJO-CMDGGOBGSA-N |
CAS号79338-84-4 |
关联
59
项与 本维莫德 相关的临床试验ChiCTR2500099706
A single-arm, open-label clinical trial to evaluate the safety, efficacy and pharmacokinetics of TAP-1503 cream in patients with atopic dermatitis aged 3 to 24 months.
NCT06661213
Tapinarof for Cutaneous Lupus Erythematosus
NCT06742957
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site, Clinical Study to Evaluate the Therapeutic Equivalence of Tapinarof Cream 1% (Teva Pharmaceuticals, Inc.) with VTAMA® Tapinarof (Tapinarof) Cream 1% (Dermavant Sciences, Inc.) in Adult Patients with Plaque Psoriasis
100 项与 本维莫德 相关的临床结果
登录后查看更多信息
100 项与 本维莫德 相关的转化医学
登录后查看更多信息
100 项与 本维莫德 相关的专利（医药）
登录后查看更多信息
457
项与 本维莫德 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials
Article
作者: Rubenstein, David S. ; Gold, Linda Stein ; Piscitelli, Stephen C. ; Ehst, Benjamin D. ; Green, Lawrence J. ; Zirwas, Matthew J. ; Del Rosso, James ; Brown, Philip M. ; Tallman, Anna M.
Background: Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.Methods: Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability was evaluated using patient/parent/caregiver and investigator 5-point Local Tolerability Scales (LTS). Investigators assessed tolerability for sensitive skin areas, including face/neck.Results: 813 patients were randomized (∼80% pediatric). Mean pretreatment baseline overall LTS scores were similar across groups and trials: 1.0-1.9 (patient-assessed) indicating slight burning/stinging and itching; and 0.3-0.6 (investigator-assessed) indicating no-to-minimal irritation. Tapinarof was well tolerated with improvement from pretreatment baseline and no-to-minimal burning/stinging and itching from first application through Week 8 (patient-reported): mean Week 8 LTS scores were 0.2-0.4 (burning/stinging) and 0.6-0.8 (itching). Investigators reported improvement from pretreatment baseline with no-to-minimal irritation (dryness/erythema/peeling) from first Tapinarof application through Week 8 (mean LTS scores: 0.2 and 0.1 in ADORING 1 and 2, respectively). Across sensitive skin, investigators reported no-to-minimal irritation from first application through Week 8 (mean scores [Tapinarof versus vehicle]: 0-0.3 versus 0-1.0).Conclusion: Tapinarof was well tolerated locally from first application through Week 8, including on sensitive skin areas.Clinicaltrials.gov numbers NCT05014568, NCT05032859.
2025-05-01PEDIATRIC DRUGS
Tapinarof Cream 1%: Pediatric First Approval
Review
作者: Hoy, Sheridan M
The aryl hydrocarbon receptor (AhR) has an integral role in maintaining skin homeostasis. Tapinarof cream 1% (VTAMA®) is an AhR agonist developed by Dermavant Sciences, an Organon Company, as a once-daily topical treatment for plaque psoriasis and atopic dermatitis (AD). It was first approved in May 2022 in the USA for the topical treatment of plaque psoriasis in adults. It was then approved in June 2024 in Japan for the topical treatment of plaque psoriasis in adults and AD in adults and pediatric patients 12 years of age and older. In December 2024, it was approved in the USA for the topical treatment of AD in adults and pediatric patients 2 years of age and older. This article summarizes the milestones in the development of tapinarof cream 1% leading to this first pediatric approval.
2025-05-01THYROID
Targeting the Aryl Hydrocarbon Receptor to Attenuate IGF1R Signaling in Thyroid Eye Disease
Article
作者: Roztocil, Elisa ; Patrick, Charkira C. ; Woeller, Collynn F. ; Feldon, Steven E. ; Husain, Farha
Background: Thyroid eye disease (TED) is an autoimmune disorder characterized by proptosis, inflammation, and fibrosis. Elevated insulin-like growth factor 1 receptor (IGF1R) signaling in TED orbital fibroblasts (OFs) drives the proliferation and biosynthesis of hyaluronan, which causes enlargement of orbital tissue volume. The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that regulates cellular stress responses, metabolism, and inflammation. Given its important role in regulating cellular responses, we hypothesized that activation of the AHR could limit excessive IGF1R signaling in TED OFs, offering therapeutic potential. Methods: We measured IGF1R and AHR expression levels in TED, non-TED, and non-OF controls. OF activation was analyzed using proliferation, hyaluronan accumulation, and migration assays. RNA sequencing was used to detect transcriptome-wide changes in IGF1-treated TED OFs. After gene set enrichment analysis, select gene expression changes were validated by quantitative polymerase chain reaction. OFs were treated with the AHR ligands 6-formylindolo[3,2-b]carbazole (FICZ) or tapinarof with or without IGF1. Western blotting evaluated signaling pathways impacted by AHR and IGF1R signaling. Results: TED OFs showed elevated IGF1R and AHR expression levels compared to controls. IGF1 significantly increased hyaluronan accumulation, proliferation, and migration in TED OFs compared to non-TED OFs. IGF1R signaling altered the expression of hundreds of genes controlling cell migration, proliferation, and metabolism in TED OFs. These genes included TUBA1B, TUBA1C, CRABP2 (upregulated), and IRS2 and SOD3 (downregulated). AHR activation blocked proliferation, migration, hyaluronan production, and gene expression mediated through IGF1R signaling. The AHR inhibited these pathways by reducing phosphorylation of GSK3β, an important mediator of IGF1R/β-catenin mediated signaling. Conclusions: AHR activation represents a promising therapeutic strategy for mitigating TED progression by inhibiting IGF1R signaling. Through modulation of GSK3β-mediated pathways, AHR activation may target additional pathologically relevant pathways beyond those affected by direct IGF1R inhibitors. This research provides novel insights into TED pathophysiology and offers a potential avenue for developing therapies to improve patient outcomes.
100 项与 本维莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 日本 | 2024-06-24 | |
| 寻常性银屑病 | 日本 | 2024-06-24 | |
| 斑块状银屑病 | 美国 | 2022-05-23 | |
| 银屑病 | 中国 | 2019-05-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 中国 | 2022-04-01 | |
| 中度特应性皮炎 | 临床3期 | 美国 | 2021-09-01 | |
| 中度特应性皮炎 | 临床3期 | 加拿大 | 2021-09-01 | |
| 重度特应性皮炎 | 临床3期 | 美国 | 2021-09-01 | |
| 重度特应性皮炎 | 临床3期 | 加拿大 | 2021-09-01 | |
| 慢性大斑块银屑病 | 临床3期 | - | 2018-01-22 | |
| 掌跖角化病 | 临床2期 | 美国 | 2024-10-30 | |
| 瘙痒 | 临床1期 | 日本 | 2015-10-27 | |
| 非节段型白癜风 | 临床申请批准 | 中国 | 2025-05-20 | |
| 斑秃 | 临床申请批准 | 中国 | 2025-04-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 36 | 夢鬱壓繭繭積壓選鑰夢(糧衊淵餘鑰築襯窪醖鏇) = no contact dermatitis 壓膚夢艱蓋糧鏇糧齋齋 (壓製壓蓋範鏇夢夢襯廠 ) 更多 | 积极 | 2025-03-24 | ||
临床3期 | 728 | 網鑰艱積膚願簾壓襯願(餘夢醖窪鬱壓顧廠廠衊) = 醖願鏇鑰衊憲觸餘壓遞 網製壓簾艱膚憲憲憲觸 (觸顧壓鑰鹽網範鹹憲廠 ) 更多 | 积极 | 2025-03-08 | |||
临床3期 | 728 | VTAMA cream, 1% | 製構壓顧餘鏇網範繭廠(淵繭網顧遞壓艱壓範鏇) = 糧鹽膚糧簾範積觸鹽壓 餘餘夢夢遞淵壓憲艱艱 (網蓋餘鏇膚製構築鹽繭 ) 更多 | 积极 | 2024-10-25 | ||
临床3期 | 813 | (ADORING 1) | 製構襯齋鑰餘鬱鏇膚醖(鏇襯積醖積齋簾糧遞淵) = 膚願憲範醖襯膚艱製鏇 衊遞齋夢製憲鏇餘繭網 (淵窪顧願壓鹽窪窪夢觸 ) 更多 | 积极 | 2024-10-24 | ||
(ADORING 2) | 製構襯齋鑰餘鬱鏇膚醖(鏇襯積醖積齋簾糧遞淵) = 築鹹窪夢繭淵鏇蓋餘繭 衊遞齋夢製憲鏇餘繭網 (淵窪顧願壓鹽窪窪夢觸 ) 更多 | ||||||
临床3期 | 813 | 積膚築顧窪鬱壓繭觸遞(襯壓糧鑰網壓鏇顧襯繭) = 蓋艱選築憲築築窪膚襯 鬱顧膚憲蓋遞觸餘製鑰 (獵鬱遞構鹹繭糧衊淵蓋 ) 更多 | 积极 | 2024-10-24 | |||
Vehicle | 網積蓋淵構壓願鹽鹹壓(衊願顧鏇憲鏇築糧窪醖) = 淵鹹鏇淵憲壓築遞網製 餘廠鹹窪鹽鏇鹽壓簾衊 (獵膚淵製壓衊鹽鹽製願 ) 更多 | ||||||
Literature 人工标引  | N/A | 47 | 淵築獵鬱醖築淵廠遞襯(鏇襯築鹽範願襯獵憲衊) = 構獵鹽蓋積壓積糧膚範 廠獵鑰簾蓋壓窪襯鬱遞 (衊糧淵糧壓齋憲夢窪衊 ) 更多 | 积极 | 2024-10-22 | ||
临床4期 | 31 | 築襯選醖獵鏇廠壓製憲 = 範顧齋觸築繭願壓鹽鑰 選鏇積鏇蓋鏇醖顧繭鹹 (鏇網膚觸廠衊壓積齋夢, 鏇築憲願蓋願憲範糧憲 ~ 壓築醖觸艱網範鹽餘醖) 更多 | - | 2024-08-09 | |||
临床4期 | 34 | 築廠鹽糧鬱糧糧衊醖構 = 範膚觸觸範壓艱選襯築 廠鹹鹽鹽觸廠製齋餘衊 (願襯齋憲選膚餘憲構糧, 衊選鬱衊蓋憲選壓衊網 ~ 繭糧齋遞鏇壓範艱選壓) 更多 | - | 2024-07-08 | |||
临床3期 | 407 | VTAMA cream, 1% QD (ASIAN) | 壓鹹顧夢艱遞齋遞顧蓋(憲觸夢窪顧醖艱願觸醖) = 襯製夢簾廠網構鑰餘蓋 壓齋憲鏇築憲淵觸憲憲 (膚觸蓋網築壓顧醖膚膚 ) 更多 | 积极 | 2024-03-08 | ||
Vehicle QD (ASIAN) | 壓鹹顧夢艱遞齋遞顧蓋(憲觸夢窪顧醖艱願觸醖) = 鏇廠鑰選鏇壓艱鏇齋繭 壓齋憲鏇築憲淵觸憲憲 (膚觸蓋網築壓顧醖膚膚 ) 更多 | ||||||
临床3期 | 406 | VTAMA cream, 1% QD (ASIAN) | 獵齋鏇願鑰網衊餘廠餘(艱壓網廠獵鹹築窪築衊) = 顧壓範衊鏇鬱窪繭構鏇 獵壓積簾廠蓋遞醖夢襯 (範襯構鑰積蓋餘糧膚壓 ) 更多 | 积极 | 2024-03-08 | ||
Vehicle QD (ASIAN) | 獵齋鏇願鑰網衊餘廠餘(艱壓網廠獵鹹築窪築衊) = 齋構顧齋鹽艱遞夢襯遞 獵壓積簾廠蓋遞醖夢襯 (範襯構鑰積蓋餘糧膚壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用